Stock info UCB | Filter  Basic-Info

Stock: UCB (Belgium 20), ISIN: BE0003739530

Last Price 101.15 Max Price 101.45
Min Price 75.30 1 Year return 42.67
Avg. Target 114.64 Expected Return 13.34 %
Sector Health Care Subsector Pharmaceuticals
Sell 0 Rating Star full 12x12Star full 12x12Star full 12x12Star full 12x12
Hold 3 Concensus Cons holdCons buy
Buy 11
Annual report 2018

UCB Group is an international pharmaceutical company from Belgium. UCB Group has around 12,000 employees. UCB Group products include ‘Keppra’, ‘Xyzal’, ‘Zyrtec’, ‘Nootropil’ and ‘Atarax’. UCB's stocks are traded on the Euronext Brussels and the company is a component of the BEL20.

UCB or Union Chimique Belge is the international bio pharmaceutical conglomerate that has been established on 18 January, 1928 by a Belgium businessman Emmanuel Janssen. The foundation of the company can be considered as a successively done conversion of a hybrid chemical firm into a patient centric pharmaceutical company. The main headquarter of the company is located in Brussels, Belgium and the other North-American headquarter is residing in the outside region of Atlanta, Georgia. The main key personalities of the company are known to be Karel Boone, Chairman and Roch Doliveux, Chief Executive Officer of the company, providing employment to approximately 12,000 people globally. The operating units of the company currently have a presence in around 40 countries with a further aim of making a network of the company and its associated partners as a cross functional industry on location all over the world, majorly focusing on severe diseases.


Shares of the company are being traded on the continuous market of Euronext Brussels, coming to the count of BEL-20 with the revenue generation of 3.4 billion €, as was the case in 2012. The overall possessions of the company come out to be around 8.9 billion € along with the total equity of 4.59 billion € (according to the data of 2010). The main products that have been manufactured by the group includes the names of Metadate, omeprazole, Xyzal, Keppra, Vimpat, Cimzia, Nootropil, Zyrtec and Atarax. There are three of the main segmentation within the structure of UCB, named as Science, People and Patients. Science section consists of Commercial partners, Research partners and In-house R&D. People section focusing on cross functional teams and can be considered as a global knowledge-sharing platform. The third and the last section include patient communities, health care professionals and caregivers. The global network of the company is made with the involvement of many of the partners starting from Biowa, ChemBridge, Evotec, Emerald, Harvard University, K.U. Leuven, Pfizer and ending up to Wilex.


Currently, the company is focusing on two of the main therapeutic fields - Central Nervous System and Immunology. The first part concentrating mainly on Parkinson's and Epilepsy diseases along with the rest-less legs syndrome and the second part is focusing on disorders like bone-loss, lupus, rheumatoid arthritis and Crohn's disease. ‘Braine-l'Alleud’ in Belgium (for CNS disorders) and ‘Slough’ in UK (for immunology department) are the two main Research Centers of Excellence associated with the company. Primary developmental locations have the presence at the locations of Atlanta, Braine-l'Alleud, Tokyo, Slough, Monheim and Research Triangle Park. A virtualized R & D collaborating platform has also been made by implementing the principles of Wikipedia by the group in which multi disciplinary teams (including the members from R&D and supply chain departments), which works for the completion of the projects of the company.


Contact info:Street: Allee de la Recherche, 60Zip Code: 1070 BrussCity: BrusselsCountry: BelgiumPhone: 32 2 559 99 99Website: www.ucb.com

Sector Review UCB

Year Turnover Total sector Market share
2005 2,341 5,222,910 0.04 %
2006 2,523 5,679,143 0.04 %
2007 3,626 6,051,420 0.06 %
2008 3,601 6,505,938 0.06 %
2009 3,116 7,059,590 0.04 %
2010 3,218 7,199,541 0.04 %
2011 3,246 7,212,887 0.05 %
2012 3,462 6,562,508 0.05 %
2013 3,411 6,365,874 0.05 %
2014 3,344 6,091,051 0.05 %
2015 3,876 6,052,014 0.06 %
2016 4,178 6,372,792 0.07 %
2017 4,530 6,539,564 0.07 %
2018 4,632 6,620,924 0.07 %
2019 4,913 7,213,990 0.07 %
2020 5,347 7,455,914 0.07 %

Advice UCB

Date Label Bank Label Stock Label Advice Label Price Label Diff Label
October 13, 2021 KBC Securities UCB Buy 120.00 15.46 %
September 16, 2021 Jefferies & Co. UCB Buy 130.00 21.96 %
September 02, 2021 JP Morgan UCB Buy 150.00 32.37 %
September 02, 2021 Barclays UCB Buy 102.00 0.54 %
August 25, 2021 Goldman Sachs UCB Buy 123.00 17.52 %
August 24, 2021 ING UCB Buy 130.00 21.96 %
August 23, 2021 UBS UCB Buy 116.00 12.54 %
August 06, 2021 HSBC UCB Hold 94.00 -7.93 %
August 03, 2021 Credit Suisse UCB Hold 95.00 -6.79 %
July 23, 2021 Deutsche Bank UCB Buy 115.00 11.78 %
July 09, 2021 Societe Generale UCB Buy 115.00 11.78 %
July 05, 2021 Morgan Stanley UCB Hold 100.00 -1.45 %
March 02, 2021 Kepler Capital Markets UCB Buy 105.00 3.38 %
November 09, 2020 DeGroof Petercam UCB Buy 110.00 7.77 %
September 17, 2020 Bryan Garnier UCB Buy 135.00 33.19 %
July 22, 2020 Sanford C. Bernstein & Co UCB Buy 120.00 25.47 %
February 20, 2020 Oddo BHF UCB Hold 87.50 1.23 %
October 16, 2019 Citigroup UCB Buy 84.00 -12.48 %
September 07, 2018 Berenberg UCB Hold 84.00 19.86 %
June 06, 2018 Natixis UCB Hold 65.00 -4.37 %
April 30, 2018 Standard & Poors UCB Buy 73.00 3.84 %
February 22, 2018 Oddo Securities UCB Buy 76.00 -2.87 %
October 24, 2017 Exane BNP Paribas UCB Hold 61.00 -14.69 %
July 31, 2015 Petercam UCB Hold 64.00 -9.33 %
July 13, 2015 Leleux Associated Brokers UCB Buy 71.25 4.07 %
August 05, 2014 Dierickx, Leys & Cie UCB Sell
June 12, 2014 ABN AMRO UCB Hold 45.00 -43.33 %
August 24, 2021 KBC Securities UCB Buy 119.00 14.75 %
June 27, 2021 KBC Securities UCB Buy 119.00 14.75 %
April 26, 2021 Morgan Stanley UCB Hold 95.00 -6.79 %
March 23, 2021 ING UCB Hold 120.00 15.46 %
March 05, 2021 Morgan Stanley UCB Hold 105.00 3.38 %
March 05, 2021 HSBC UCB Hold 87.00 -16.61 %
March 03, 2021 UBS UCB Hold 90.00 -12.72 %
February 11, 2021 Goldman Sachs UCB Buy 120.00 15.46 %
January 22, 2021 Barclays UCB Buy 110.00 7.77 %
January 20, 2021 Credit Suisse UCB Hold 90.00 -12.72 %
January 08, 2021 Jefferies & Co. UCB Hold 96.00 -5.68 %
January 05, 2021 JP Morgan UCB Hold 100.00 -1.45 %
November 25, 2020 UBS UCB Hold 97.00 -4.59 %



News UCB

Analysts expect over 2020 rising revenue UCB

On Monday the Belgian company UCB will publish its past quarters results. For this year UCB's revenue will be around 5,19 billion euros. This is according to the average of the analysts' estimates. This is slightly more than 2019's revenue of 4,91 billion euros....

UCB strong outperformer among the Belgian stocks

Because of the huge profits of 49 percent this year the share belongs to one of the best shares of Belgium. Since the start of this year, the average Belgian stock rose year around 11 percent in value. Over the past 3 months the stock price increased (+26 percent)....

Analysts foresee more revenue UCB

Next Monday the Belgian company UCB will publish its past quarters results. Over the current book year the total revenue will be 4,7 billion euros (consensus estimates). This is slightly more than 2017's revenue of 4,63 billion euros. Historical revenues andresults...

Analysts think UCB is fairly priced

UCB's stock price seems, partly because of the recent share price rises, to be in line with most of the estimates. Most of the analysts say UCB is fairly priced now. Currently the company is being followed by 13 analysts. The average of the target prices for the...

Analysts think UCB is fairly priced

UCB's stock price seems, partly because of the recent share price rises, to be in line with most of the estimates. Most of the analysts say UCB is fairly priced now. Currently the company is being followed by 13 analysts. The average of the target prices for the...



Annual reports UCB

2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020

Profile UCB

UCB

(BE0003739530)/ UCB

The past year gave good returns for UCB investors

The period between December 2015 and December 2016 was a loss-making period for the investors in UCB. The stock lost around 25 percent. Over the past 5 years the stock rose a massive 89,51 percent. UCB's revenues between 2011 and 2015 were quite stable and moved between 3,46 billion euros and 3,88 billion euros. UCB's net results between 2011 and 2015 were far from constant and moved between 221 million euros and 315 million euros.

UCB has her headquarter located in Brussels. The core activities of UCB are in the pharmaceutical sector. Over the past 10 years the global pharmaceutical companies gained around 75 percent. Measured since 2011 the sector is 147 percent higher and over the past 12 months (December 2015-December 2016) there is a minus of 75 percent.

Over the past 5 years the Belgian company paid out dividends. UCB's dividend return over the period 2011 - 2015 was around 4,2 percent per year. Over the past 5 years the company raised it's dividends each year. Because of the yearly increased dividends UCB can be called a kind of dividend aristocrat.

The Belgian company had ultimo 2015 approximately 8684 thousand employees on it's payroll.

UCB financed with a quite low debt position

Last year the balance sheet of the Belgian company was worth 10,96 billion euros. At the end of 2015 the total debt positon equaled 5,28 billion euros. This is around 48,23 percent of the total balance sheet. As per the end of 2015 UCB's price/earnings-ratio equaled 44. So investors paid for 1 stock 44 times the earnings per share of 2015. We could say that based on it's price/earnings-ratio and dividend yield the Belgian stock can be seen as a value stock.

At the end of 2015 the Belgian company's market capitalization equaled around 15,73 billion euros. At the end of 2015 around 192,08 million stocks were listed.

All UCB's financial reports are available here. More information about UCB can be found it's website. .


Results UCB

Results
2015
2016
2017
2018
2019
2020
Revenue
3,876
4,178
4,530
4,632
4,913
5,347
Costs
3,253
3,658
3,777
3,832
4,121
4,615
Profit
623
520
753
800
792
732
Margin of profit
16.07
12.45
16.62
17.27
16.12
13.69
ROI
10.98
9.31
12.95
12.68
11.25
10.07

Balance UCB

Balance
2015
2016
2017
2018
2019
2020
Equity
5,672
5,584
5,813
6,310
7,039
7,271
Debt
5,284
4,628
4,104
4,204
4,042
6,048
Total assets
10,956
10,212
9,917
10,514
11,081
13,319
Solvency
51.77
54.68
58.62
60.02
63.52
54.59
Cash
1,304
799
1,112
1,356
1,432
1,522
Cashflow
246
427
927
1,089
882
1,081
Employees
7,900
7,400
7,478
7,495
0
Revenue per employee
0.49
0.56
0.61
0.62
0.0
Cashflow / Debt
0.05
0.09
0.23
0.26
0.22
0.18

Details UCB

Details
2016
2017
2018
2019
2020
Price
83.23
60.91
66.18
71.30
70.90
Eps
2.76
4.00
4.24
4.23
3.77
Price/earnings-ratio
30.16
15.23
15.61
16.86
26.83
Dividend
0.81
0.83
0.85
0.87
0.89
Dividend %
0.97 %
1.36 %
1.28 %
1.22 %
0.88 %
Payout %
0.29
0.21
0.20
0.21
0.24
Book value
29.60
30.89
33.40
37.33
38.47
Market to book
0.36
0.51
0.50
0.52
0.38
Cashflow per stock
2.26
4.93
5.76
4.68
5.72
Stocks
189
188
189
189
189
Market Cap
15.703.61
11.463.93
12.501.93
13.445.97
19.119.88

Dividend UCB

Dividend
2015
2016
2017
2018
2019
2020
Dividend
1.10
0.81
0.83
0.85
0.87
0.89
Dividend %
1.74 %
0.97 %
1.36 %
1.28 %
1.22 %
0.88 %
Payout %
0.34
0.29
0.21
0.20
0.21
0.24

Price info UCB

Date
Price
21 Oct 2021
101.15
20 Oct 2021
101.45
18 Oct 2021
98.88
16 Oct 2021
98.08
14 Oct 2021
97.22
11 Oct 2021
98.32
08 Oct 2021
97.70
07 Oct 2021
96.94
06 Oct 2021
98.98
05 Oct 2021
98.16
04 Oct 2021
97.04
02 Oct 2021
97.04
01 Oct 2021
96.80
27 Sep 2021
95.12
24 Sep 2021
94.30
23 Sep 2021
95.28
22 Sep 2021
95.24
21 Sep 2021
96.04
20 Sep 2021
94.40
17 Sep 2021
92.30
16 Sep 2021
92.86
15 Sep 2021
90.20
14 Sep 2021
90.88
13 Sep 2021
90.32
10 Sep 2021
91.20
09 Sep 2021
92.68
08 Sep 2021
94.30
07 Sep 2021
97.34
06 Sep 2021
98.32
03 Sep 2021
98.04